Hypersensitivity to the active substances, to other sulphonamide derivatives, to dihydropyridine derivatives, or to any of the excipients.
Second and third trimesters of pregnancy (see Precautions and Use in Pregnancy & Lactation).
Hepatic impairment, biliary cirrhosis or cholestasis.
Severe renal impairment (GFR <30 ml/min/1.73 m2), anuria and patients undergoing dialysis.
Concomitant use of Exforge HCT with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see Precautions and Interactions).
Refractory hypokalaemia, hyponatraemia, hypercalcaemia, and symptomatic hyperuricaemia.
Shock (including cardiogenic shock).
Obstruction of the outflow tract of the left ventricle (e.g. hypertrophic obstructive cardiomyopathy and high grade aortic stenosis).
Haemodynamically unstable heart failure after acute myocardial infarction.